CanAg Diagnostics
1992
FOUNDED
M&A
STATUS
M&A
LATEST DEAL TYPE
Description
Developer of immunological reagents. The company develops monoclonal antibodies for the treatment of cancer, brain damage and tumors.
Website
Formerly Known As
Centocor Diagnostics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare
Acquirer
Fujirebio Diagnostics
Primary Office
- Elof Lindälvs gata 13
- 414 55 Gothenburg
- Sweden
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore CanAg Diagnostics’s full profile, request a free trial.
CanAg Diagnostics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 31-May-2006 | Completed | Generating Revenue | |||
| 2. Angel (individual) | 01-Jan-2001 | Completed | Generating Revenue | |||
| 1. Early Stage VC | Completed | Startup |
CanAg Diagnostics Former Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Industrifonden | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Líftæknisjóðurinn MP BIO hf | Venture Capital | Minority | 000 0000 | 000000 0 |
CanAg Diagnostics Executive Team (3)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Börje Karlsson | Co-Founder | ||
| Leif Lindholm | Co-Founder |
1 Former Executive
You’re viewing 2 of 3 executives. Get the full list »